Group I Propranolol &misoprostol N = 64 | Group II placebo &misoprostol N = 64 | P-value | ||||||
---|---|---|---|---|---|---|---|---|
Indication of induction | Post date (n %) | 39 | 60.9% | 44 | 68.8% | 0.355 NS 1 | ||
ROM (n %) | 18 | 28.1% | 10 | 15.6% | 0.08 NS 1 | |||
HTN (n %) | 6 | 9.4% | 9 | 14.1% | 0.41*NS 1 | |||
GDM (n %) | 1 | 1.6% | 1 | 1.6% | 1.0 NS 2 | |||
Mode of delivery | NVD (n %) | 45 | 70.3% | 39 | 60.9% | 0.264 NS 2 | ||
CS (n %) | 19 | 29.7% | 25 | 39.1% | ||||
Duration of Latent phase (hours) (45 cases in group I, 39 cases in group II) | Mean ± SD | 7.9 ± 5.6 | 9.2 ± 6.03 | 0.017 S 3 | ||||
Duration of Active Phase (hours) (45 cases in group I, 39 cases in group II) | Mean ± SD | 3.9 ± 2.7 | 3.5 ± 2.9 | 0.425 NS 3 | ||||
Induction-delivery interval (hours) (45 cases in group I, 39 cases in group II) | Mean ± SD | 11.8 ± 8.1 | 12.6 ± 8.9 | 0.027 S 3 | ||||
Misoprostol dose (No. of doses) (45 cases in group I, 39 cases in group II) | 1 dose (n %) | 14 | 31.1% | 14 | 35.9% | 0.79 NS 2 | ||
2 dose (n %) | 28 | 62.2% | 22 | 56.4% | ||||
3 dose (n %) | 2 | 4.4% | 2 | 5.1% | ||||
4 dose (n %) | 1 | 2.2% | 1 | 2.6% | ||||
Oxytocin dose(units) (45 cases in group I, 39 cases in group II) | 0 unit (n %) | 26 | 57.8% | 22 | 56.4% | 0.834 2 NS | ||
5 units (n %) | 14 | 31.1% | 13 | 33.3% | ||||
10 units (n %) | 4 | 8.9% | 2 | 5.1% | ||||
15 units (n %) | 1 | 2.2% | 2 | 5.1% | ||||
Indication of CS (19 cases in group I, 25 cases in group II) | Failed progress (n %) | 7 | 36.8% | 9 | 36% | 0.713 NS 2 | ||
Fetal distress (n) %) | 10 | 52.6% | 15 | 60% | ||||
Failed induction (n %) | 2 | 10.5% | 1 | 4% |